Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders

Shitara, 2006, Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions, Pharmacol Ther, 112, 71, 10.1016/j.pharmthera.2006.03.003 Bersot, 2011, Drug therapy for hypercholesterolemia and dyslipidemia, 877 Law, 2006, Statin safety: a systematic review, Am J Cardiol, 97, 52C, 10.1016/j.amjcard.2005.12.010 Wang, 2008, Pleiotropic effects of statin therapy: molecular mechanisms and clinical results, Trends Mol Med, 14, 37, 10.1016/j.molmed.2007.11.004 Liao, 2005, Pleiotropic effects of statins, Annu Rev Pharmacol Toxicol, 45, 89, 10.1146/annurev.pharmtox.45.120403.095748 Butterfield, 2011, Atorvastatin and Abeta(1-40): not as simple as cholesterol reduction in brain and relevance to alzheimer disease, Exp Neurol, 228, 15, 10.1016/j.expneurol.2010.12.014 Cole, 2006, Isoprenoids and Alzheimer's disease: a complex relationship, Neurobiol Dis, 22, 209, 10.1016/j.nbd.2005.11.007 Cordle, 2005, Mechanisms of statin-mediated inhibition of small g-protein function, J Biol Chem, 280, 34202, 10.1074/jbc.M505268200 McTaggart, 2006, Isoprenylated proteins, Cell Mol Life Sci, 63, 255, 10.1007/s00018-005-5298-6 Corsini, 1999, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol Ther, 84, 413, 10.1016/S0163-7258(99)00045-5 Littarru, 2007, Coenzyme q10 and statins: biochemical and clinical implications, Mitochondrion, 7, S168, 10.1016/j.mito.2007.03.002 Marcoff, 2007, The role of coenzyme q10 in statin-associated myopathy: a systematic review, J Am Coll Cardiol, 49, 2231, 10.1016/j.jacc.2007.02.049 Greenwood, 2006, Statin therapy and autoimmune disease: from protein prenylation to immunomodulation, Nat Rev Immunol, 6, 358, 10.1038/nri1839 van der Most, 2009, Statins: mechanisms of neuroprotection, Prog Neurobiol, 88, 64, 10.1016/j.pneurobio.2009.02.002 Lapchak, 2010, Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a rock inhibitor but not the thrombolytic tissue plasminogen activator, Brain Res, 1344, 217, 10.1016/j.brainres.2010.05.035 Ghosh, 2009, Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of parkinson's disease, J Neurosci, 29, 13543, 10.1523/JNEUROSCI.4144-09.2009 Miron, 2007, Simvastatin regulates oligodendroglial process dynamics and survival, Glia, 55, 130, 10.1002/glia.20441 Wagstaff, 2003, Statin-associated memory loss: analysis of 60 case reports and review of the literature, Pharmacotherapy, 23, 871, 10.1592/phco.23.7.871.32720 Paintlia, 2008, Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis, Mol Pharmacol, 73, 1381, 10.1124/mol.107.044230 Cerezo-Guisado, 2007, Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts, Biochem J, 401, 175, 10.1042/BJ20060731 Meske, 2003, Blockade of hmg-coa reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease, Eur J Neurosci, 17, 93, 10.1046/j.1460-9568.2003.02433.x Nusse, 1996, Localization of g alpha 0 to growth cones in pc12 cells: role of g alpha 0 association with receptors and g beta gamma, J Cell Sci, 109, 221, 10.1242/jcs.109.1.221 Qiu, 1991, Ras isoprenylation is required for ras-induced but not for ngf-induced neuronal differentiation of pc12 cells, J Cell Biol, 115, 795, 10.1083/jcb.115.3.795 Farah, 1998, A rho-associated protein kinase, rokalpha, binds insulin receptor substrate-1 and modulates insulin signaling, J Biol Chem, 273, 4740, 10.1074/jbc.273.8.4740 Sundaresan, 1996, Regulation of reactive-oxygen-species generation in fibroblasts by rac1, Biochem J, 318, 379, 10.1042/bj3180379 Paintlia, 2009, Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis, Glia, 57, 182, 10.1002/glia.20745 Weber, 2006, Statins in the treatment of central nervous system autoimmune disease, J Neuroimmunol, 178, 140, 10.1016/j.jneuroim.2006.06.006 Smolders, 2010, Simvastatin interferes with process outgrowth and branching of oligodendrocytes, J Neurosci Res, 88, 3361, 10.1002/jnr.22490 Xiang, 2009, Simvastatin induces cell death in a mouse cerebellar slice culture (csc) model of developmental myelination, Exp Neurol, 215, 41, 10.1016/j.expneurol.2008.09.010 Li, 2010, Simvastatin attenuates hypomyelination induced by hypoxia–ischemia in neonatal rats, Neurol Res, 32, 945, 10.1179/016164110X12670144737774 Maier, 2009, Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes, Glia, 57, 402, 10.1002/glia.20769 Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol Aging, 21, 383, 10.1016/S0197-4580(00)00124-X Pahan, 1997, Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages, J Clin Invest, 100, 2671, 10.1172/JCI119812 Champagne, 2003, The cholesterol-lowering drug probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer's disease, Neuroscience, 121, 99, 10.1016/S0306-4522(03)00361-0 Lindberg, 2005, Effects of statins on microglia, J Neurosci Res, 82, 10, 10.1002/jnr.20615 Orr, 2008, Statins in the spectrum of neurologic disease, Curr Atheroscler Rep, 10, 11, 10.1007/s11883-008-0003-5 Wallerath, 2003, Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects, J Am Coll Cardiol, 41, 471, 10.1016/S0735-1097(02)02826-7 Landmesser, 2005, Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans, Circulation, 111, 2356, 10.1161/01.CIR.0000164260.82417.3F Laufs, 1998, Upregulation of endothelial nitric oxide synthase by hmg coa reductase inhibitors, Circulation, 97, 1129, 10.1161/01.CIR.97.12.1129 Kureishi, 2000, The hmg-coa reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals, Nat Med, 6, 1004, 10.1038/79510 Kurinami, 2008, Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model, Int J Mol Med, 21, 531 Tong, 2009, Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice, Neurobiol Dis, 35, 406, 10.1016/j.nbd.2009.06.003 Riekse, 2006, Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid, J Alzheimers Dis, 10, 399, 10.3233/JAD-2006-10408 Piermartiri, 2010, Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1–40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage, Exp Neurol, 226, 274, 10.1016/j.expneurol.2010.08.030 Murphy, 2010, Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs, J Alzheimers Dis, 22, 135, 10.3233/JAD-2010-100639 Barone, 2011, Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of alzheimer disease: a novel mechanism of action, Pharmacol Res, 63, 172, 10.1016/j.phrs.2010.12.007 Bliznakov, 1998, Biochemical and clinical consequences of inhibiting coenzyme q(10) biosynthesis by lipid-lowering hmg-coa reductase inhibitors (statins): a critical overview, Adv Ther, 15, 218 Langsjoen, 2005, Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation, Biofactors, 25, 147, 10.1002/biof.5520250116 Parker, 2003, Influence of 3-hydroxy-3-methylglutaryl-coa (hmg-coa) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature, Atherosclerosis, 169, 19, 10.1016/S0021-9150(03)00100-X Vaya, 2007, Oxysterols, cholesterol homeostasis, and alzheimer disease, J Neurochem, 102, 1727, 10.1111/j.1471-4159.2007.04689.x Han, 2007, Prevention of 7-ketocholesterol-induced mitochondrial damage and cell death by calmodulin inhibition, Brain Res, 1137, 11, 10.1016/j.brainres.2006.12.041 Panini, 2001, Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized ldl/oxysterol, J Lipid Res, 42, 1678, 10.1016/S0022-2275(20)32223-9 Trousson, 2009, 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase a2 type iia via lxr beta and pxr, J Neurochem, 109, 945, 10.1111/j.1471-4159.2009.06009.x Arca, 2007, Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy, Free Radic Biol Med, 42, 698, 10.1016/j.freeradbiomed.2006.12.013 Kathir, 2010, Equivalent lipid oxidation profiles in advanced atherosclerotic lesions of carotid endarterectomy plaques obtained from symptomatic type 2 diabetic and nondiabetic subjects, Free Radic Biol Med, 49, 481, 10.1016/j.freeradbiomed.2010.05.006 Larsson, 2007, In vivo interconversion of 7beta-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress, Free Radic Biol Med, 43, 695, 10.1016/j.freeradbiomed.2007.04.033 Berthier, 2004, Involvement of a calcium-dependent dephosphorylation of bad associated with the localization of trpc-1 within lipid rafts in 7-ketocholesterol-induced Thp-1 cell apoptosis, Cell Death Differ, 11, 897, 10.1038/sj.cdd.4401434 Kumar, 2010, A GC/MS-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats, Anal Biochem Thelen, 2006, High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, J Clin Pharmacol, 46, 812, 10.1177/0091270006289851 Beydoun, 2010, Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment, J Epidemiol Community Health Li, 2010, Age-varying association between statin use and incident Alzheimer's disease, J Am Geriatr Soc, 58, 1311, 10.1111/j.1532-5415.2010.02906.x Smeeth, 2009, Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials, Br J Clin Pharmacol, 67, 99, 10.1111/j.1365-2125.2008.03308.x Haag, 2009, Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study, J Neurol Neurosurg Psychiatry, 80, 13, 10.1136/jnnp.2008.150433 Horsdal, 2009, Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study, Alzheimer Dis Assoc Disord, 23, 18, 10.1097/WAD.0b013e318180f55b Rosenberg, 2008, Women and statin use: a women's health advocacy perspective, Scand Cardiovasc J, 42, 268, 10.1080/14017430801993180 Sparks, 2008, Reduced risk of incident AD with elective statin use in a clinical trial cohort, Curr Alzheimer Res, 5, 416, 10.2174/156720508785132316 Cramer, 2008, Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study, Neurology, 71, 344, 10.1212/01.wnl.0000319647.15752.7b Benito-Leon, 2010, Statins and cognitive functioning in the elderly: a population-based study, J Alzheimers Dis, 21, 95, 10.3233/JAD-2010-100180 Hippisley-Cox, 2010, Unintended effects of statins in men and women in england and wales: population based cohort study using the qresearch database, BMJ, 340, c2197, 10.1136/bmj.c2197 Sparks, 2010, Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort, Neurodegener Dis, 7, 183, 10.1159/000295660 Trompet, 2010, Pravastatin and cognitive function in the elderly. Results of the prosper study, J Neurol, 257, 85, 10.1007/s00415-009-5271-7 Shepherd, 1999, The design of a prospective study of pravastatin in the elderly at risk (prosper). Prosper study group. Prospective study of pravastatin in the elderly at risk, Am J Cardiol, 84, 1192, 10.1016/S0002-9149(99)00533-0 Feldman, 2010, Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: leade, Neurology, 74, 956, 10.1212/WNL.0b013e3181d6476a Waters, 2010, Exploring new indications for statins beyond atherosclerosis: successes and setbacks, J Cardiol, 55, 155, 10.1016/j.jjcc.2009.12.003 Sparks, 2006, Statin therapy in Alzheimer's disease, Acta Neurol Scand Suppl, 185, 78, 10.1111/j.1600-0404.2006.00689.x Sparks, 2006, Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the alzheimer's disease cholesterol-lowering treatment (adclt) trial, Acta Neurol Scand Suppl, 185, 3, 10.1111/j.1600-0404.2006.00690.x McGuinness, 2010, Statins for the treatment of dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD007514.pub2 O’Brien, 2010, Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the british association for psychopharmacology, J Psychopharmacol Querfurth, 2010, Alzheimer's disease, N Engl J Med, 362, 329, 10.1056/NEJMra0909142 Mayeux, 2010, Clinical practice. Early Alzheimer's disease, N Engl J Med, 362, 2194, 10.1056/NEJMcp0910236 Simons, 2002, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol, 52, 346, 10.1002/ana.10292 Saher, 2005, High cholesterol level is essential for myelin membrane growth, Nat Neurosci, 8, 468, 10.1038/nn1426 Reiman, 2010, Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging, Neuroimage, 49, 169, 10.1016/j.neuroimage.2009.07.025 Fonseca, 2010, Cholesterol and statins in Alzheimer's disease: current controversies, Exp Neurol, 223, 282, 10.1016/j.expneurol.2009.09.013 McGuinness, 2009, Statins for the prevention of dementia, Cochrane Database Syst Rev, 10.1002/14651858.CD003160.pub2 Hoglund, 2004, Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins, Arch Neurol, 61, 333, 10.1001/archneur.61.3.333 Evans, 2009, Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease, Dement Geriatr Cogn Disord, 27, 519, 10.1159/000221835 Jann, 2002, Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors, Clin Pharmacokinet, 41, 719, 10.2165/00003088-200241100-00003 Kiani, 2007, Medicinal importance of grapefruit juice and its interaction with various drugs, Nutr J, 6, 33, 10.1186/1475-2891-6-33 Stump, 2006, Management of grapefruit-drug interactions, Am Fam Physician, 74, 605 Hare, 2003, Grapefruit juice and potential drug interactions, Consult Pharm, 18, 466 Dreier, 2004, Statin-associated rhabdomyolysis triggered by grapefruit consumption, Neurology, 62, 670, 10.1212/WNL.62.4.670 Werba, 2008, The effect of green tea on simvastatin tolerability, Ann Intern Med, 149, 286, 10.7326/0003-4819-149-4-200808190-00019 Perluigi, 2009, Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis, Proteomics Clin Appl, 3, 682, 10.1002/prca.200800161 Sultana, 2010, Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease, Antioxid Redox Signal, 12, 327, 10.1089/ars.2009.2810 Sultana, 2009, Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of ad: role of Abeta in pathogenesis, Acta Neuropathol, 118, 131, 10.1007/s00401-009-0517-0 Butterfield, 2001, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide, Trends Mol Med, 7, 548, 10.1016/S1471-4914(01)02173-6 Bellosta, 2004, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation, 109, III50, 10.1161/01.CIR.0000131519.15067.1f Mukhtar, 2005, Pitavastatin, Int J Clin Pract, 59, 239, 10.1111/j.1742-1241.2005.00461.x